Ivan Civettini

Dr. Ivan Civettini

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2023 in British Journal of Haematology
Verified
Journal Article
Open access
ICIvan Civettini
Ivan Civettini
AZArianna Zappaterra
Arianna Zappaterra
BGBianca Maria Granelli
Bianca Maria Granelli
GRGiovanni Rindone
Giovanni Rindone
AAAndrea Aroldi
Andrea Aroldi
FCFabrizio Cavalca
Fabrizio Cavalca
Summary: In a first‐of‐its‐kind study, we assessed the capabilities of large language models (LLMs) in making complex decisions in haematopoietic stem cell transplantation. The evaluation was conducted not only for Generative Pre‐trained Transformer 4 (GPT‐4) but also conducted on other artificial intelligence models: PaLm 2 and Llama‐2. Using detailed haematological histories that include both clinical, molecular and donor data, we conducted a triple‐blind survey to compare LLMs to haematology residents. We found that residents significantly outperformed LLMs (p = 0.02), particularly in transplant eligibility assessment (p = 0.01). Our triple‐blind methodology aimed to mitigate potential biases in evaluating LLMs and revealed both their promise and limitations in deciphering complex haematological clinical scenarios.

4 April 2024 in Blood
Verified
Journal Article
Open access
ICIlaria Crespiatico
Ilaria Crespiatico
MZMattia Zaghi
Mattia Zaghi
CMCristina Mastini
Cristina Mastini
DDDeborah D'Aliberti
Deborah D'Aliberti
MMMario Mauri
Mario Mauri
VLValentina Fabiola Ilenia Lavoro
Valentina Fabiola Ilenia Lavoro
SETBP1 mutations are found in various clonal myeloid disorders. However, it is unclear whether they can initiate leukemia, because SETBP1 mutations typically appear as later events during oncogenesis. To answer this question, we generated a mouse model expressing mutated SETBP1 in hematopoietic tissue: this model showed profound alterations in the differentiation program of hematopoietic progenitors and developed a myeloid neoplasm with megakaryocytic dysplasia, splenomegaly, and bone marrow fibrosis, prompting us to investigate SETBP1 mutations in a cohort of 36 triple-negative primary myelofibrosis (TN-PMF) cases. We identified 2 distinct subgroups, one carrying SETBP1 mutations and the other completely devoid of somatic variants. Clinically, a striking difference in disease aggressiveness was noted, with patients with SETBP1 mutation showing a much worse clinical course. In contrast to myelodysplastic/myeloproliferative neoplasms, in which SETBP1 mutations are mostly found as a late clonal event, single-cell clonal hierarchy reconstruction in 3 patients with TN-PMF from our cohort revealed SETBP1 to be a very early event, suggesting that the phenotype of the different SETBP1+ disorders may be shaped by the opposite hierarchy of the same clonal SETBP1 variants.

20 May 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
CKCamille Kockerols
Camille Kockerols
PVPeter J. M. Valk
Peter J. M. Valk
SDStéphanie Dulucq
Stéphanie Dulucq
FNFranck‐Emmanuel Nicolini
Franck‐Emmanuel Nicolini
FMFrançois‐Xavier Mahon
François‐Xavier Mahon
PWPeter E. Westerweel
Peter E. Westerweel

16 December 2022 in European Journal of Haematology
Verified
Journal Article
Open access
EIElena Inzoli
Elena Inzoli
ECElena Crisa
Elena Crisa
NPNovella Pugliese
Novella Pugliese
ICIvan Civettini
Ivan Civettini
GLGiuseppe Lanzarone
Giuseppe Lanzarone
Elena Maria ElliElena Maria Elli
Elena Maria Elli
Objectives: Erythropoiesis-stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B-ESA), in myelofibrosis (MF) is not well established.Methods: This study retrospectively collected data on 96 MF patients treated with B-ESA (alpha/zeta) for the management of anemia to assess safety, efficacy (anemia response [AR]), and survival.Results: Seventy-seven patients (80%) obtained AR. The median time to AR was 2.5 months. In multivariate analysis, significant predictive factors of AR were transfusion independency (p = .006) and ferritin levels < 200 ng/ml (p = .009) at baseline. After a median follow-up of 43.8 months from diagnosis, 38 patients (39%) died, 11 (28.9%) from leukemic evolution. Only two patients (2.5%) stopped B-ESA for toxicity. The 24-month survival was significantly affected by response to B-ESA (70.8% in AR vs. 55.3% in non-responder patients, p = .016). In multivariate analysis, age & LE; 70 years (p = .029) and Hb > 8.5 g/dl (p = .047) at baseline were significantly associated with improved survival, with a trend for longer survival in AR patients (p = .06).Conclusions: B-ESA seems to be an effective and well-tolerated option for anemia treatment in the MF setting. This strategy deserves further clinical investigation.

16 December 2022 in British Journal of Haematology
Verified
Journal Article
Closed access
ICIvan Civettini
Ivan Civettini
SBSilvia Anna Maria Bolis
Silvia Anna Maria Bolis

12 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
FMFederica Malighetti
Federica Malighetti
MVMatteo Villa
Matteo Villa
MMMario Mauri
Mario Mauri
SPSimone Piane
Simone Piane
VCValentina Crippa
Valentina Crippa
AAAndrea Aroldi
Andrea Aroldi
Background: Anaplastic lymphoma kinase (ALK) plays a role in the development of lymphoma, lung cancer and neuroblastoma. While tyrosine kinase inhibitors (TKIs) have improved treatment outcomes, relapse remains a challenge due to on-target mutations and off-target resistance mechanisms. ALK-positive (ALK+) tumors can evade the immune system, partly through tumor-associated macrophages (TAMs) that facilitate immune escape. Cancer cells use “don’t eat me” signals (DEMs), such as CD47, to resist TAMs-mediated phagocytosis. TKIs may upregulate pro-phagocytic stimuli (i.e., calreticulin, CALR), suggesting a potential therapeutic benefit in combining TKIs with an anti-CD47 monoclonal antibody (mAb). However, the impact of this combination on both TKIs-sensitive and resistant ALK+ tumors requires further investigation. Methods: A panel of TKIs-sensitive and resistant ALK+ cancer subtypes was assessed for CALR and CD47 expression over time using flow cytometry. Flow cytometry co-culture and fluorescent microscopy assays were employed to evaluate phagocytosis under various treatment conditions. Results: ALK inhibitors increased CALR expression in both TKIs-sensitive and off-target resistant ALK+ cancer cells. Prolonged TKIs exposure also led to CD47 upregulation. The combination of ALK inhibitors and anti-CD47 mAb significantly enhanced phagocytosis compared to anti-CD47 alone, as confirmed by flow cytometry and fluorescent microscopy. Conclusions: Anti-CD47 mAb can quench DEMs while exposing pro-phagocytic signals, promoting tumor cell phagocytosis. ALK inhibitors induced immunogenic cell damage by upregulating CALR in both sensitive and off-target resistant tumors. Continuous TKIs exposure in off-target resistant settings also resulted in the upregulation of CD47 over time. Combining TKIs with a CD47 blockade may offer therapeutic benefits in ALK+ cancers, especially in overcoming off-target resistance where TKIs alone are less effective.